KOPRANNSEKopran Limited· PharmaceuticalsMediumNeutral
Announced Fri, 10 Apr · 16:30 IST

Kopran Limited has informed the Exchange about Amalgamation/Merger

Nclt Scheme FiledStrategic Transactions View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.3%1-day move
₹157.70
prior close
₹154.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.0-0.6-0.1+0.2-1.3+1.0+0.2-1.7-3.6+2.7+4.3-1.9+16.7+31.0
Up moveDown movePending
AI summary

Kopran Limited has provided an update on the Scheme of Amalgamation where Kopran Laboratories Limited (Transferor Company) will merge into Kopran Limited (Transferee Company). The NCLT Mumbai Bench, through its order dated April 9, 2026, has directed both companies to convene meetings for Equity Shareholders, Secured Creditors, and Unsecured Creditors. This is a standard procedural step in the merger approval process under Section 230 to 232 of the Companies Act, 2013. The merger remains subject to applicable regulatory and other approvals.

Likely market impact

This is a positive development as the merger moves forward with NCLT oversight. Shareholders should monitor the upcoming creditor and shareholder meetings as their approval will be required for the scheme to proceed. No immediate impact on stock price expected until the deal closes.